X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.prnewswire.com/news-releases/ipsen-and-medison-pharma-announce-health-canada-approval-of-bylvay-odevixibat-for-the-treatment-of-pruritus-due-to-progressive-familial-intrahepatic-cholestasis-pfic-301986009.html
https://www.globenewswire.com//news-release/2023/10/23/2764369/0/en/Ipsen-updates-on-E-U-Marketing-Authorisation-Application-for-odevixibat-in-Alagille-syndrome.html
https://www.ema.europa.eu/en/documents/overview/bylvay-epar-medicine-overview_en.pdf
https://www.prnewswire.com/news-releases/eqt-private-equity-to-sell-ellab-following-transformation-into-a-leading-validation--monitoring-provider-for-the-biotech-and-pharmaceutical-industries-301856367.html
https://www.prnewswire.com/news-releases/jadeite-medicines-receives-orphan-drug-designation-for-odevixibat-in-progressive-familial-intrahepatic-cholestasis-pfic-from-the-ministry-of-health-labour-and-welfare-of-japan-and-will-also-initiate-phase-3-trial-of-odevixibat--301855717.html
https://www.fiercepharma.com/pharma/after-albireo-buyout-ipsens-bylvay-picks-new-fda-approved-use
https://www.globenewswire.com/news-release/2023/05/17/2670630/0/en/Ipsen-to-present-new-Bylvay-odevixibat-data-at-annual-ESPGHAN-congress-showcasing-commitment-to-furthering-treatment-for-rare-cholestatic-liver-diseases.html
https://www.globenewswire.com/news-release/2022/12/19/2576315/0/en/Albireo-Submits-Bylvay-Alagille-Syndrome-Regulatory-Filings-to-FDA-and-EMA.html
https://www.globenewswire.com/news-release/2022/11/30/2564968/0/en/Reimbursed-Access-to-Bylvay-odevixibat-Approved-in-France-for-Patients-with-PFIC-1-2.html
https://www.globenewswire.com/news-release/2022/11/07/2549734/0/en/Bylvay-odevixibat-Data-Presented-at-AASLD-The-Liver-Meeting-2022-Demonstrating-Native-Liver-Survival-in-Children-Across-PFIC-Types.html
https://www.globenewswire.com/news-release/2022/11/01/2545497/0/en/Albireo-to-Present-Late-Breaking-Bylvay-odevixibat-Data-at-AASLD-2022.html
https://www.globenewswire.com/news-release/2022/10/13/2533864/0/en/Albireo-Presents-Data-on-Greater-Efficacy-in-PFIC-with-Earlier-Bylvay-Treatment-at-NASPGHAN.html
https://www.globenewswire.com/news-release/2022/10/11/2531659/0/en/Albireo-Reports-Positive-Topline-Data-from-Phase-3-Trial-of-Bylvay-odevixibat-in-Alagille-Syndrome.html
https://www.fiercepharma.com/pharma/albireos-bylvay-aces-test-alagille-syndrome-setting-it-second-pediatric-liver-disease
https://www.globenewswire.com/news-release/2022/09/06/2510346/0/en/Italian-Medicines-Agency-Approves-Reimbursed-Access-to-Bylvay-odevixibat-For-Patients-with-All-PFIC-Types.html
https://www.prnewswire.com/news-releases/medison-pharma-announces-the-expansion-of-its-partnership-with-albireo-to-a-multi-regional-agreement-to-commercialize-odevixibat-in-canada-and-israel-301606428.html
https://www.globenewswire.com/news-release/2022/08/15/2498561/0/en/Albireo-Reports-Q2-2022-Financial-Results-and-Business-Update.html
https://www.globenewswire.com/news-release/2022/06/24/2468749/0/en/Albireo-Presents-New-Bylvay-odevixibat-Data-at-Annual-ESPGHAN-Congress.html
https://www.globenewswire.com/news-release/2022/03/29/2411916/0/en/Albireo-Completes-Enrollment-in-Pivotal-Phase-3-ASSERT-Study-of-BylvayTM-odevixibat-in-Alagille-Syndrome.html
http://www.pharmafile.com/news/608379/nice-recommends-albireo-s-bylvay-odevixibat-all-pfic-types
https://www.fiercebiotech.com/biotech/albireo-cmo-horn-out-doors-five-months-after-u-s-eu-approvals-rare-liver-disease-drug
https://www.globenewswire.com/news-release/2021/09/15/2297519/0/en/Albireo-Announces-Bylvay-odevixibat-Now-Available-in-Germany.html
https://www.biospace.com/article/releases/albireo-receives-uk-mhra-approval-of-bylvay-odevixibat-/?s=71
https://www.ema.europa.eu/en/documents/overview/bylvay-epar-medicine-overview_en.pdf
https://www.globenewswire.com/news-release/2021/06/21/2250044/0/en/Albireo-Announces-Expanded-Phase-3-Data-on-Bylvay-odevixibat-and-A3907-at-Upcoming-EASL-International-Liver-Congress.html
https://www.globenewswire.com/news-release/2021/02/11/2174134/0/en/Albireo-Presents-Odevixibat-Commercialization-Road-to-1-Billion.html
https://ir.albireopharma.com/news-releases/news-release-details/albireo-initiates-global-phase-3-clinical-trial-odevixibat
https://ir.albireopharma.com/news-releases/news-release-details/albireo-initiates-global-phase-3-clinical-trial-odevixibat
http://www.pharmatimes.com/news/albireo_submits_rare_liver_disease_med_odevixibat_to_fda_and_ema_1359878
http://www.globenewswire.com/news-release/2020/11/13/2126490/0/en/New-Phase-3-Data-at-AASLD-Show-Durable-Response-to-Odevixibat-in-a-Rare-Pediatric-Liver-Disease.html
https://www.globenewswire.com/news-release/2020/11/02/2118417/0/en/Albireo-s-Odevixibat-PFIC-Phase-3-Results-Accepted-for-AASLD-Late-Breakers.html
Market Place
Share 
